Supply-duration traps to avoid
A lower per-vial price on a 90-day supply is not automatically cheaper per dose if titration moves the patient to a new strength before the vial is used. GLP-1 programs face this risk most often — lock per-dose cost at each titration step for both monthly and multi-month options. For TRT, quarterly testosterone may reduce shipments but tie up patient cash flow; model fulfillment savings against inventory waste if protocols change.
Amortize RxFul SaaS across doses shipped. $997/mo Bronze spread over 50 monthly GLP patients is a different per-dose platform burden than 200 patients — duration choice changes shipment count and therefore fulfillment fees on Silver+ volume tiers.